Scholarlink

<p>Multiple Sclerosis (MS) is a multifactorial and complex disease; currently only few and relatively invasive biomarkers have shown a moderate prognostic value. Finding new, more reliable and non-invasive biomarkers could allow earlier MS diagnosis and improve the conduction of therapeutic and rehabilitative protocols. We investigated whether miR-199a-3p and miR-103a-3p can be useful for this purpose. Fifty-seven healthy controls (HC) and 185 people with a diagnosis of either progressive (P-MS; N=63), relapsing (R-MS; N=63), or within 2 years since the diagnosis (short disease duration, S-MS; n=59) MS were enrolled, serum concentration of miR-199a-3p and miR-103a-3p was measured in all individuals by droplet digital PCR (ddPCR). Whereas miR-199a-3p was significantly up-regulated in the overall group of MS patients compared to HC, miR-103a-3p was significantly up-regulated in S-MS and R-MS, but not in P-MS. Interestingly, both miRNAs were up-regulated in S-MS, and their combined measurement had a good power to discriminate between S-MS and HC. These results suggest that the measurement of miR-199a-3p and miR-103a-3p serum concentration might be a useful biomarker for MS, particularly in the very initial stages of disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum miR-199a-3p and miR-103a-3p are possible biomarkers for the onset of multiple sclerosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Simone Agostini,
  • Roberta Mancuso,
  • Maria Barbara Pasanisi,
  • Riccardo Nuzzi,
  • Laura Antolini,
  • Domenico Caputo,
  • Marco Rovaris,
  • Mario Clerici

摘要

Multiple Sclerosis (MS) is a multifactorial and complex disease; currently only few and relatively invasive biomarkers have shown a moderate prognostic value. Finding new, more reliable and non-invasive biomarkers could allow earlier MS diagnosis and improve the conduction of therapeutic and rehabilitative protocols. We investigated whether miR-199a-3p and miR-103a-3p can be useful for this purpose. Fifty-seven healthy controls (HC) and 185 people with a diagnosis of either progressive (P-MS; N=63), relapsing (R-MS; N=63), or within 2 years since the diagnosis (short disease duration, S-MS; n=59) MS were enrolled, serum concentration of miR-199a-3p and miR-103a-3p was measured in all individuals by droplet digital PCR (ddPCR). Whereas miR-199a-3p was significantly up-regulated in the overall group of MS patients compared to HC, miR-103a-3p was significantly up-regulated in S-MS and R-MS, but not in P-MS. Interestingly, both miRNAs were up-regulated in S-MS, and their combined measurement had a good power to discriminate between S-MS and HC. These results suggest that the measurement of miR-199a-3p and miR-103a-3p serum concentration might be a useful biomarker for MS, particularly in the very initial stages of disease.